Basic—Liver, Pancreas, and Biliary TractThe Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease
Section snippets
Patients
We enrolled 415 patients with biopsy-proven NAFLD at different stages of disease from Newcastle and Turin hospitals according to the regulations and ethical requirements of the participating centers. All patients had clinical features and liver biopsies diagnostic of NAFLD. Women and men consuming greater than 14 or 21 units of alcohol per week, respectively, were excluded, as were any individuals with viral or autoimmune liver diseases. Clinical and laboratory data were collected on the date
KLF6 Expression Is Increased in Association With More Advanced Stages of NAFLD
KLF6 is a ubiquitous transcription factor and immediate early gene induced in response to stressful stimuli. We have compared its expression at the mRNA level using 2 different sets of TaqMan real-time primers and probe, one of which quantifies all isoforms of KLF6 (KLF6 Total) and one of which quantifies the full-length, wild-type version only (KLF6 wt). Both are expressed as an RQ value, relative to the same control gene (glyceraldehyde-3-phosphate dehydrogenase) and the same comparator
Discussion
NAFLD is increasingly common in Western societies. Established predictors of those likely to develop progressive disease characterized by advanced fibrosis include age, increased BMI, and an increased blood glucose level.27 Why some individuals with these risk factors progress and others do not is unclear, but twin and ethnic studies suggest that genetic factors play a role.5, 6 To date, SNPs in a number of genes have been associated with NAFLD severity, including microsomal triglyceride
References (33)
- et al.
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference
Hepatology
(2003) - et al.
The natural history of nonalcoholic fatty liver disease: a population-based cohort study
Gastroenterology
(2005) - et al.
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
Gastroenterology
(2002) - et al.
Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds
Am J Med
(2000) - et al.
Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease
Am J Gastroenterol
(2001) - et al.
Transcriptional activation of urokinase by the Kruppel-like factor Zf9/COPEB activates latent TGF-beta1 in vascular endothelial cells
Blood
(2000) - et al.
A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene
J Biol Chem
(1997) - et al.
Early genes induced in hepatic stellate cells during wound healing
Gene
(1997) - et al.
Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1Potential mechanisms for autocrine fibrogenesis in response to injury
J Biol Chem
(1998) - et al.
Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats
J Hepatol
(2003)
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation
J Hepatol
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions
Am J Gastroenterol
Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis
J Hepatol
The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population
J Hepatol
Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis
J Hepatol
Cause-specific mortality in type 2 diabetesThe Verona Diabetes Study
Diabetes Care
Cited by (0)
Supported by grants from GlaskoSmithKline (H.L.R.); Newcastle upon Tyne Hospitals Special Trustees (H.L.R.); European Association for Study of the Liver Sheila Sherlock fellowship (L.M.); European Research Advisory Board (C.P.D.; H.L.R.), and National Institutes of Health grant DK56621 (S.L.F.).